Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about PONS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| NITRIC OXIDE | associated_with | phenotype | 0.45 |
| NOS1 | associated_with | gene | 0.45 |
| NEURONS | associated_with | cell_type | 0.45 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| iPSC-derived astrocyte-neuron co-culture mitochondrial transfer in PD | exploratory | Parkinson's disease | 0.900 | 0.00 | iPSC-derived dopaminergic neur | proposed | N/A |
| Gestational haloperidol exposure effects on hippocampal gene expressio | validation | schizophrenia | 0.900 | 0.00 | pregnant mice and offspring | proposed | N/A |
| NPM1-IRF1 protein interaction validation | exploratory | cancer | 0.900 | 0.00 | cultured cells | proposed | N/A |
| NPM1 knockout tumor progression study in syngeneic mice | validation | cancer | 0.900 | 0.00 | syngeneic mice with subcutaneo | proposed | N/A |
| PH-PS treatment in 5×FAD Alzheimer's disease mice | validation | Alzheimer's disease | 0.900 | 0.00 | 5×FAD transgenic mice | proposed | N/A |
| SIRPα modulation in mouse models of Alzheimer's disease | validation | Alzheimer's disease | 0.900 | 0.00 | mouse models of Alzheimer's di | proposed | N/A |
| Dual-luciferase assay for miR-137-3p target validation | exploratory | schizophrenia | 0.800 | 0.00 | cell culture system with dual- | proposed | N/A |
| In vitro T-cell killing assay with OVA-presenting tumor cells | exploratory | cancer | 0.800 | 0.00 | OVA-presenting tumor cells and | proposed | N/A |
| Microglial SIRPα expression in human Alzheimer's disease tissue | exploratory | Alzheimer's disease | 0.800 | 0.00 | human brain tissue | proposed | N/A |
| Proposed experiment from debate on Astrocytes adopt A1 (neurotoxic) an | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | completed | $100,000 |
| Metabolic Pathway-Targeted Therapy in ALS | clinical | ALS | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Animal Model Comparison for Neurodegenerative Disease Therapeutics | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinso | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protec | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| GLP-1 Agonist Neuroprotection Mechanism in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| GLP-1 Agonist Responder Prediction Study — Precision Medicine for Neur | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Biomechanical Impact Profiles and Chronic Traumatic Encephalopathy Phe | clinical | Neurodegeneration | 0.400 | 0.50 | in_silico | proposed | $180,000 |
| Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk Cohorts | clinical | ALS | 0.400 | 0.50 | human | proposed | $6,550,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| NPM1 inhibits tumoral antigen presentation to promote immune evasion and tumor p [PMID:39402629] | Wang X, Chai Y, Quan Y, Wang J, Song J, | J Hematol Oncol | 2024 | 1 |
| Complement C1q/C3-CR3 signaling pathway mediates abnormal microglial phagocytosi [PMID:38642614] | Han QQ, Shen SY, Liang LF, Chen XR, Yu J | Brain Behav Immun | 2024 | 1 |
| Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. [PMID:37384704] | Zhang T, Xu D, Trefts E, Lv M, Inuzuka H | Science | 2023 | 1 |
| Significance of NPM1 Gene Mutations in AML. [PMID:34576201] | Hindley A, Catherwood MA, McMullin MF, M | Int J Mol Sci | 2021 | 1 |
| NPM1-mutated acute myeloid leukemia: from bench to bedside. [PMID:32609823] | Falini B, Brunetti L, Sportoletti P, Mar | Blood | 2020 | 1 |
| Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK [PMID:31693892] | Wang Y, An H, Liu T, Qin C, Sesaki H, Gu | Cell Rep | 2019 | 1 |
| AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking Sy [PMID:30057310] | Song X, Zhu S, Chen P, Hou W, Wen Q, Liu | Curr Biol | 2018 | 1 |
| Methylation of HPA axis related genes in men with hypersexual disorder. [PMID:28319850] | Jokinen J, Boström AE, Chatzittofis A, C | Psychoneuroendocrinology | 2017 | 1 |
| Insights into the regulation of neuronal viability by nucleophosmin/B23. [PMID:25908633] | Pfister JA, D'Mello SR | Exp Biol Med (Maywood) | 2015 | 1 |
| Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuro [PMID:26121488] | Hang L, Thundyil J, Lim KL | Ann N Y Acad Sci | 2015 | 1 |
| Development of alopecia areata is associated with higher central and peripheral [PMID:19020552] | Zhang X, Yu M, Yu W, Weinberg J, Shapiro | J Invest Dermatol | 2009 | 1 |
| Functions of the histone chaperone nucleolin in diseases. [PMID:17484127] | Storck S, Shukla M, Dimitrov S, Bouvet P | Subcell Biochem | 2007 | 1 |
| AMPKα1 Deficiency in Macrophages Impairs Tendon Regeneration and Tendon Stem Cel [PMID:41694579] | Zhu L, Wang Y, Shi X, Yu M, Cai X, Chen | International journal of biolo | 2026 | 0 |
| Single-cell transcriptome analysis reveals a cellular immune response in common [PMID:41692207] | Shi X, Ji G, Liu D, Zhao T, Tian S, Li S | International journal of biolo | 2026 | 0 |
| Farrerol ameliorates hepatic insulin resistance via AMPKα1/mTOR/SREBP-1 pathway: [PMID:41702183] | Li Y, Feng X, Zheng L | Tissue & cell | 2026 | 0 |
| Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypome [PMID:41035402] | Short NJ, Loghavi S, Yilmaz M, Karrar O, | Haematologica | 2026 | 0 |
| The gain-of-function TREM2-T96K mutation increases risk for Alzheimer's disease [PMID:41109213] | Pilat DJ, Le H, Prokopenko D, Lin CJ, Ei | Neuron | 2026 | 0 |
| Role of TREM2 in neuroinflammation. [PMID:41213496] | Abdulkhaliq AA, Alasiri G, Almoghrabi Y, | Exp Neurol | 2026 | 0 |
| A dysregulated hepcidin-iron axis impairs antiviral immunity and induces lethal [PMID:41365298] | Xu Y, Chen X, Fang R, Wang X, Zhang Y et | Immunity | 2026 | 0 |
| A Unified Model: Chromatin-Bound Multicomponent Condensates. [PMID:41481253] | Lau BK, Haarer EL, Ahn JH, Wang GG | Cancer Res | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning PONS in their description or question text
Score: 0.663 · translational-neuroscience · 2026-04-16
**Molecular Mechanism and Rationale** Choline kinase alpha (CHKA) represents a critical regulatory enzyme in phospholip
Score: 0.653 · neurodegeneration · 2026-04-02
## Mechanistic Overview Nucleolar Stress Response Normalization starts from the claim that modulating NPM1 within the di
Score: 0.640 · neurodegeneration · 2026-04-25
This hypothesis posits that mild hyperbaric oxidative stress activates Nrf2-ARE transcriptional programs, upregulating S
Score: 0.626 · alzheimers · 2026-04-04
## Mechanistic Overview Microglial TREM2 downregulation impairs damage-associated response in late-stage Alzheimer's dis
Score: 0.622 · neurodegeneration · 2026-04-21
## Mechanistic Overview TOM/TIM Complex Disruption Triggering Mitochondrial Integrated Stress Response (mtISR) starts fr
Score: 0.614 · neurodegeneration · 2026-04-17
## Mechanistic Overview Dose-Response Framework: PINK1/Parkin Mitophagy as the Critical Mediator Linking HBOT Parameters
Score: 0.604 · neurodegeneration · 2026-04-28
The debate supports carrying forward TREM2 enhancement as a way to restore protective microglial response and reduce dow
Score: 0.579 · neurodegeneration · 2026-04-16
## Mechanistic Overview Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction starts
Score: 0.565 · alzheimers · 2026-04-04
## Mechanistic Overview Temporal Gating of Microglial Responses starts from the claim that modulating CLOCK, ARNTL withi
Score: 0.526 · neurodegeneration · 2026-04-04
## Mechanistic Overview Neuronal Integrated Stress Response Modulation starts from the claim that modulating EIF2AK3 (PE
Score: 0.520 · neurodegeneration · 2026-04-22
## Mechanistic Overview Telomere Attrition and DNA Damage Response Activation Induces Microglial Senescence starts from
Score: 0.455 · neuroinflammation · 2026-04-27
Different myelopathy etiologies trigger conserved oligodendrocyte stress response program mediated by ER stress and inte
Score: 0.455 · neurodegeneration · 2026-04-27
Selective activation of ribosome-associated quality control pathways to eliminate seed-templated nascent proteins